anastrozole has been researched along with palbociclib in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (50.00) | 24.3611 |
| 2020's | 5 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Andre, F; Bartlett, CH; Beaney, M; Bliss, JM; Cristofanilli, M; Dowsett, M; Fribbens, C; Garcia-Murillas, I; Hrebien, S; Jiang, J; Johnston, SR; Kilburn, L; Koehler, M; Loi, S; Loibl, S; O'Leary, B; Turner, NC | 1 |
| Gilarranz, YJ; Lopez-Tarruella, S; Martin, M | 1 |
| Niraula, S; Ocana, A | 1 |
| Chia, SK; McLeod, D; Paterson, A; Pritchard, KI; Provencher, L; Rayson, D; Simmons, C | 1 |
| Arpino, G; Bachelot, T; Cristofanilli, M; De Laurentiis, M; De Placido, P; De Placido, S; Del Mastro, L; Generali, D; Giordano, A; Giuliano, M; Jerusalem, G; Milani, M; Pistilli, B; Prat, A; Puglisi, F; Rognoni, C; Schettini, F; Thomas, G; Venturini, S | 1 |
| Drumm, C; Grogan, L; Maguire, M; Mullally, W; O'Kane, M; Redmond, M; Woods, G | 1 |
| Agostinetto, E; de Azambuja, E; Debien, V; Lambertini, M; Marta, GN; Piccart-Gebhart, M | 1 |
| Cai, R; Li, Q; Luo, Y; Ma, F; Mo, H; Wang, J; Xu, B; Yuan, P; Zhang, P | 1 |
| Adamchuk, H; Alonso-Romero, JL; Badovinac Crnjevic, T; Bardia, A; Berzoy, O; Blancas, I; Chan, D; Fasching, PA; Fernando, TM; Ferreira, E; Hurvitz, SA; López-Valverde, V; Moore, HM; Park, YH; Pérez-Moreno, PD; Quiroga, V; Salgado, M; Spera, G; Steinseifer, J; Vasiliev, A; Xue, C; Yardley, DA; Zamora-Auñón, P | 1 |
| Ades, F; Filian, J; Huang, N; Jerusalem, G; Mazzei-Abba, A; Nikolinakos, P; Prat, A; Reinisch, M; Ruiz-Borrego, M; Salgado, R; Saura, C; Tolaney, SM | 1 |
4 review(s) available for anastrozole and palbociclib
| Article | Year |
|---|---|
Endocrine therapy for hormone treatment-naïve advanced breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Estradiol; Female; Fulvestrant; Humans; Letrozole; Nitriles; Piperazines; Pyridines; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles | 2016 |
Mechanism of drug resistance in relation to site of metastasis: Meta-analyses of randomized controlled trials in advanced breast cancer according to anticancer strategy.
Topics: Anastrozole; Androstadienes; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Disease-Free Survival; Drug Resistance, Neoplasm; Estradiol; Everolimus; Female; Fulvestrant; Humans; Letrozole; Nitriles; Piperazines; Pyridines; Randomized Controlled Trials as Topic; Trastuzumab; Triazoles | 2016 |
Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis.
Topics: Aminopyridines; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Bevacizumab; Breast Neoplasms; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Everolimus; Female; Fulvestrant; Humans; Letrozole; Network Meta-Analysis; Paclitaxel; Piperazines; Postmenopause; Progression-Free Survival; Purines; Pyridines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone | 2019 |
CDK4/6 and PI3K inhibitors: A new promise for patients with HER2-positive breast cancer.
Topics: Aminopyridines; Anastrozole; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Immunological; Benzimidazoles; Breast Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Fulvestrant; Humans; Letrozole; Phosphoinositide-3 Kinase Inhibitors; Piperazines; Protein Kinase Inhibitors; Purines; Pyridines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Trastuzumab | 2021 |
3 trial(s) available for anastrozole and palbociclib
| Article | Year |
|---|---|
Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer.
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; DNA, Neoplasm; Estradiol; Estrogen Receptor alpha; Female; Fulvestrant; Humans; Middle Aged; Nitriles; Piperazines; Prospective Studies; Pyridines; Retrospective Studies; Triazoles | 2016 |
Neoadjuvant palbociclib plus either giredestrant or anastrozole in oestrogen receptor-positive, HER2-negative, early breast cancer (coopERA Breast Cancer): an open-label, randomised, controlled, phase 2 study.
Topics: Anastrozole; Breast Neoplasms; Female; Humans; Ki-67 Antigen; Middle Aged; Neoadjuvant Therapy; Receptors, Estrogen | 2023 |
Neoadjuvant nivolumab + palbociclib + anastrozole for oestrogen receptor-positive/human epidermal growth factor receptor 2-negative primary breast cancer: Results from CheckMate 7A8.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Neoadjuvant Therapy; Nivolumab; Pneumonia; Receptor, ErbB-2; Receptors, Estrogen | 2023 |
3 other study(ies) available for anastrozole and palbociclib
| Article | Year |
|---|---|
Enhancing Endocrine Therapy Combination Strategies for the Treatment of Postmenopausal HR+/HER2- Advanced Breast Cancer.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Circulating Tumor DNA; Disease-Free Survival; Estradiol; Female; Fulvestrant; Humans; Letrozole; Mutation; Neoplastic Cells, Circulating; Nitriles; Nuclear Proteins; Piperazines; Postmenopause; Pyridines; Receptor, ErbB-2; Receptors, Estrogen; Transcription Factors; Triazoles | 2017 |
A case of delayed-onset scarring alopecia in a 75-year-old woman.
Topics: Aged; Alopecia; Anastrozole; Aromatase Inhibitors; Biopsy; Bone Density Conservation Agents; Breast Neoplasms; Cicatrix; Diagnosis, Differential; Drug Therapy, Combination; Erythema; Female; Humans; Immunohistochemistry; Neoplasm Metastasis; Piperazines; Protein Kinase Inhibitors; Pyridines; Scalp; Telangiectasis; Zoledronic Acid | 2020 |
Treatment patterns and clinical outcomes in patients with metastatic breast cancer treated with palbociclib-based therapies: real-world data in the Han population.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Everolimus; Female; Fulvestrant; Humans; Letrozole; Piperazines; Pyridines; Receptor, ErbB-2; Receptors, Estrogen; Toremifene | 2022 |